CO-TECHSTARS
Techstars, the worldwide network that helps entrepreneurs succeed, and the Ministry of Communications and Information Technology of the Kingdom of Saudi Arabia today announced a partnership to launch The Riyadh Techstars Accelerator . The accelerator joins Saudi Arabia's budding startup ecosystem to work with startups and entrepreneurs building and growing their businesses in the Middle East and North Africa, underscoring Techstars’ mission of making innovation and entrepreneurship more accessible and inclusive to more entrepreneurs.
The Riyadh Techstars Accelerator will focus on attracting startups to MENA and paving the way for future innovation in the region’s digital economy. While the accelerator will be Techstars’ first in Saudi Arabia, the organization has been active in the region for years through more than 700 Techstars Startup Weekend events, the Techstars Dubai Accelerator and the Techstars Hub71 Accelerator in Abu Dhabi.
The accelerator is an extension of earlier cooperation between the Ministry and Techstars last July through the Techstars Startup Weekend COVID-19 KSA , where more than 550 Saudi entrepreneurs, of which two thirds were female, attended virtual panels, workshops and networking events to address challenges created by the COVID-19 pandemic.
“With entrepreneurship on the rise in Saudi Arabia, and the unwavering community commitment to developing a strong startup ecosystem in the region, putting down roots in Riyadh is something we’ve been looking forward to,” said Gagan Bhatia, Techstars General Manager. “We’re excited to work with MCIT to drive innovation in the Kingdom, supporting entrepreneurs and helping them advance their ideas and businesses in the region. At Techstars, we believe that great ideas can come from anywhere. We look forward to making entrepreneurship more accessible and bringing more opportunities to more entrepreneurs in MENA through this partnership.”
The Riyadh Techstars Accelerator will begin accepting applications May 10, 2021, for a 13-week program that will take place from November 2021 through February 2022. A Techstars Managing Director will lead the accelerator with support from a Techstars program manager, along with leadership and mentors from MCIT. Participants in the three-month program will receive funding, hands-on mentorship from the Techstars and MCIT networks, access to curated workshops and resources, and access to the Techstars global network for life.
“Technology and innovation-based entrepreneurship is a key enabler to driving the achievement of Vision 2030, our nation’s blueprint for social transformation and economic diversification. We have a young population, 70% of whom are youth. These are our digital natives and we want to leverage their energy and curiosity to leapfrog with innovation,” said Dr. Ahmed Altheneyan, Deputy Minister for Future Skills and Digital Entrepreneurship. “The ministry and Techstars will come together to scale the impact of their combined resources and capabilities to truly accelerate digital entrepreneurship, across the Kingdom, where we are already witnessing the growth of a vibrant venture capital investment community, rapid technology adoption, and how digital transformation is allowing companies to re-imagine themselves to become more competitive.”
Startups interested in the accelerator are encouraged to learn more by visiting The Riyadh Techstars Accelerator page or by expressing interest here . Corporations interested in learning more about Techstars Accelerators and Techstars’ dedication to corporate innovation can learn more at techstars.com/corporate-innovation-partnerships .
About Techstars
The Techstars worldwide network helps entrepreneurs succeed. Founded in 2006, Techstars began with three simple ideas—entrepreneurs create a better future for everyone, collaboration drives innovation, and great ideas can come from anywhere. Now we are on a mission to enable every person on the planet to contribute to, and benefit from the success of entrepreneurs. In addition to operating accelerator programs and venture capital funds, we do this by connecting startups, investors, corporations, and cities to help build thriving startup communities. Techstars has invested in more than 2,400 companies with a combined market cap of more than $204B. www.techstars.com
About MCIT
MCIT is responsible for building a robust and cutting-edge digital architecture so that digital transformation accelerates and thus supports the orientations of the Saudi Vision 2030, which aims to promote the information and communication technology sector’s role in order to build a digital society, a digital government, a thriving digital economy, and an innovative future for the Kingdom.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210331006021/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Hemato-Oncology Trials: AOP Health Presents New Results at Top Congress ASH7.12.2025 17:00:00 CET | Press release
AOP Health continues to advance its clinical research program in myeloproliferative neoplasms, a special group of rare blood cancers. The company, specialized in rare diseases, presented the results of two scientific investigations at the 67th American Society of Hematology Association (ASH) Annual Meeting 2025 held in Orlando, FL, USA. The results provide new insights in treatment strategies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251207587915/en/ Dr. Martin Steinhart, CEO AOP Health; Photo credit: AOP Health/Studio Koekart ROP-ET and BESREMI PASS One of the clinical studies, ROP-ET, examined the use of ropeginterferon alfa-2b in people with essential thrombocythemia (ET), a disease in which the body produces too many platelets. The trial, a prospective, multicenter, single-arm phase III study, investigated the safety and efficacy of ropeginterferon alfa-2b in ET patients unable to receive available cytoreductive th
CoMotion GLOBAL 2025 Launches in Riyadh: Global Mobility Leaders Unite in Saudi Capital to Chart Urban Future7.12.2025 13:00:00 CET | Press release
Summit debuts Mayors in Motion initiative and CoMotion Urban Visionary Distinction as Riyadh showcases its rise as global mobility testbed Riyadh is rapidly becoming one of the world's most ambitious urban mobility laboratories, where next-generation technologies move from blueprint to real-world deployment on city streets at unprecedented scale. CoMotion GLOBAL 2025, the world's most influential gathering of urban mobility leaders, opens today in Riyadh for a three-day summit bringing together innovators from Africa, Asia, Europe, the Americas, and the Middle East. Running December 7-9, the event will explore how electrification, autonomy, AI-enabled transport, and giga-project urbanism are reshaping cities worldwide. The summit will spotlight everything from high-performance EVs and breakthrough autonomous fleets to emerging-market transport solutions and new mobility models, demonstrating how the Kingdom is opening new pathways for global mobility leadership. Strategic Partnerships
Deciphera Announces Oral Presentation of Positive Topline Results from Phase 2a Study of Sapablursen in Polycythemia Vera at the 67th American Society of Hematology (ASH) Annual Meeting6.12.2025 15:30:00 CET | Press release
Results from Phase 2a IMPRSSION study demonstrate sapablursen significantly reduced phlebotomy rate, controlled hematocrit and increased serum hepcidin Sapablursen was generally safe and well tolerated Results support further development of sapablursen in a Phase 3 study Deciphera Pharmaceuticals, a member of Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced the oral presentation of positive results from the Phase 2a IMPRSSION study of sapablursen in patients with polycythemia vera (PV) at the 67th American Society of Hematology (ASH) Annual Meeting, taking place December 6-9, 2025, in Orlando, FL. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251206361611/en/ The results were presented by Ionis Pharmaceuticals, who discovered and developed sapablursen and conducted the IMPRSSION study. In March 2025, Ionis and Ono entered into a license agreement in which On
Protagonist and Takeda Present Longer-Term Data at ASH 2025 Showing Rusfertide Delivers Durable Response and Hematocrit Control in Polycythemia Vera6.12.2025 15:30:00 CET | Press release
52-Week Results from the Phase 3 VERIFY Study of Rusfertide Demonstrated Sustained Hematocrit Control and Response, Defined by Absence of Phlebotomy Eligibility, with No New Safety SignalsThese Data Build on Positive 32-Week Primary Analysis from VERIFY, Which Met its Primary Efficacy Endpoint and All Four Key Secondary EndpointsPatients Crossing Over from Placebo to Rusfertide at 32 Weeks Achieved a Similar Response Rate to Those Initially Randomized to Rusfertide, with 77.9% Achieving Absence of Phlebotomy Eligibility Between Weeks 40-52Four-Year Results from the Combined REVIVE and Long-Term Extension THRIVE Study Demonstrated a 13-Fold Reduction in Annual Rate of Phlebotomies from Baseline Protagonist Therapeutics, Inc. (“Protagonist”) (NASDAQ:PTGX) and Takeda (TSE:4502/NYSE:TAK) announce that new 52-week results from the pivotal Phase 3 VERIFY study evaluating rusfertide in patients with polycythemia vera (PV) will be presented in an oral presentation at the 67th American Society
Vertex Presents New Data on CASGEVY®, Including First-Ever Data in Children Ages 5-11 Years, at the American Society of Hematology Annual Meeting and Announces Plan for Global Regulatory Submissions6.12.2025 13:01:00 CET | Press release
- Data from pivotal studies of CASGEVY in children ages 5-11 years with severe sickle cell disease or transfusion-dependent beta thalassemia demonstrates the transformative potential of the therapy in younger patients -- Efficacy and safety data in children 5-11 years are consistent with the durable and positive benefit/risk profile established from clinical studies in patients 12 years of age and older -- Vertex expects to initiate global regulatory submissions for CASGEVY in children 5-11 years in 1H 2026 - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced data from multiple studies demonstrating the clinical benefits of CASGEVY® (exagamglogene autotemcel) in people ages 5 years and older living with severe sickle cell disease (SCD) or transfusion-dependent beta thalassemia (TDT). The results, including the first presentation of clinical data from pivotal studies in children ages 5-11 years, and longer-term data from the pivotal studies of people with severe SCD and
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom